Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension

Scand Cardiovasc J. 2017 Oct;51(5):261-270. doi: 10.1080/14017431.2017.1359419. Epub 2017 Aug 4.

Abstract

Objectives: Pulmonary hypertension (PH) is a serious condition where diagnosis often is delayed due to unspecific symptoms. New methods to diagnose and differentiate PH earlier would therefore be of great value. The aim of this study was therefore to evaluate the relationship between circulating angiogenic and inflammatory biomarkers and various hemodynamic variables in relation to different causes of PH.

Design: Plasma samples from 63 patients at diagnosis were extracted from Lund Cardio Pulmonary Register, separated into pulmonary arterial hypertension (PAH, n = 22), chronic thromboembolic pulmonary hypertension (CTEPH, n = 15) and left heart disease (LHD) with (n = 21) and without (n = 5) PH. Blood samples from eight control subjects devoid of PH were additionally evaluated. Plasma concentrations of angiogenic (PlGF, Tie2, VEGF-A, VEGF-D, bFGF, sFlt-1) and inflammatory (IL-6, IL-8, TNF-α) biomarkers were analysed and related to hemodynamic variables.

Results: SFlt-1 (p < .004) and VEGF-A (p < .035) were higher in all PH groups compared to controls. TNF-α (p < .030) were elevated in PAH patients in relation to the other PH groups as well as controls. Likewise, plasma VEGF-D (p < .008) were elevated in LHD with PH compared to the other groups with PH and controls. In PAH, higher sFlt-1 concentrations correlated to a worse state of hemodynamics.

Conclusions: Our findings indicate that sFlt-1 and VEGF-A may be future tools when discriminating PH from non-PH. Moreover, TNF-α may differentiate PAH and VEGF- D may differentiate LHD with PH, from the other groups with PH, as well as controls. SFlt-1 may furthermore play a role as a future marker of disease severity.

Keywords: Angiogenesis; hemodynamics; inflammation; plasma biomarkers; pulmonary hypertension differentiation; sFlt-1.

MeSH terms

  • Adult
  • Aged
  • Angiogenic Proteins / blood*
  • Biomarkers / blood
  • Diagnosis, Differential
  • Female
  • Hemodynamics*
  • Humans
  • Hypertension, Pulmonary / blood*
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Inflammation Mediators / blood*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / diagnosis
  • Pulmonary Embolism / physiopathology
  • Registries
  • Risk Factors
  • Severity of Illness Index
  • Sweden
  • Tumor Necrosis Factor-alpha / blood
  • Vascular Endothelial Growth Factor A / blood
  • Vascular Endothelial Growth Factor Receptor-1 / blood
  • Ventricular Dysfunction, Left / blood
  • Ventricular Dysfunction, Left / complications
  • Ventricular Dysfunction, Left / diagnosis
  • Ventricular Dysfunction, Left / physiopathology

Substances

  • Angiogenic Proteins
  • Biomarkers
  • Inflammation Mediators
  • Tumor Necrosis Factor-alpha
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1